Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography

Atherosclerosis

Volumn 210, Issue 1, 2010, Pages 226-231

  Cavusoglu, Erdal ^a,b   Ruwende, Cyril ^c   Chopra, Vineet ^b   Poludasu, Shyam ^a   Yanamadala, Sunitha ^c   Frishman, William H ^d   Eng, Calvin ^b   Pinsky, David J ^c   Marmur, Jonathan D ^a  

^a SUNY Downstate Medical Center   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

ADMA; Biomarker; Diabetes mellitus; Myocardial infarction; Nitric oxide; Prognosis

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; N(G),N(G) DIMETHYLARGININE;

ADVERSE OUTCOME; AGED; AMINO ACID BLOOD LEVEL; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE MARKER; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; STROKE;

AGED; ARGININE; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DIABETES COMPLICATIONS; HUMANS; MALE; MYOCARDIAL INFARCTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STROKE;

EID: 77952430963     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.10.034     Document Type: Article

References (31)

1. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327:524-526.
2. Palmer R.M., Ashton D.S., Moncada S. Vascular endothelial cells synthesize nitric oxide from l-arginine. Nature 1988, 333:664-666.
3. Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997, 100:2153-2157.
4. Cooke J.P. Does ADMA cause endothelial dysfunction?. Arterioscler Thromb Vasc Biol 2000, 20:2032-2037.
5. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575.
6. Suda O., Tsutsui M., Morishita T., et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004, 24:1682-1688.
7. Abbasi F., Asagmi T., Cooke J.P., et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001, 88:1201-1203.
8. Tarnow L., Hovind P., Teerlink T., Stehouwer C.D., Parving H.H. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004, 27:765-769.
9. Malecki M.T., Undas A., Cyganek K., et al. Plasma asymmetric dimethylarginine (ADMA) is associated with retinopathy in type 2 diabetes. Diabetes Care 2007, 30:2899-2901.
10. Cavusoglu E., Ruwende C., Chopra V., et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 2006, 27:2300-2309.
11. Cavusoglu E., Ruwende C., Chopra V., et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 2006, 151(1101):e1-8.
12. Boger R.H., Bode-Boger S.M., Szuba A., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998, 98:1842-1847.
13. Lundman P., Eriksson M.J., Stuhlinger M., Cooke J.P., Hamsten A., Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001, 38:111-116.
14. Surdacki A., Nowicki M., Sandmann J., et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999, 33:652-658.
15. Boger R.H., Bode-Boger S.M., Thiele W., Junker W., Alexander K., Frolich J.C. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997, 95:2068-2074.
16. Stuhlinger M.C., Abbasi F., Chu J.W., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002, 287:1420-1426.
17. Zoccali C., Bode-Boger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358:2113-2117.
18. Mittermayer F., Krzyzanowska K., Exner M., et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 2006, 26:2536-2540.
19. Lu T.M., Ding Y.A., Lin S.J., Lee W.S., Tai H.C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003, 24:1912-1919.
20. Krempl T.K., Maas R., Sydow K., Meinertz T., Boger R.H., Kahler J. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 2005, 26:1846-1851.
21. Cavusoglu E., Ruwende C., Chopra V., et al. Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography. Coron Artery Dis 2009, 20:112-117.
22. Schnabel R., Blankenberg S., Lubos E., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005, 97:e53-e59.
23. Krzyzanowska K., Mittermayer F., Wolzt M., Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 2007, 30:1834-1839.
24. Lajer M., Tarnow L., Jorsal A., Teerlink T., Parving H.H., Rossing P. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2008, 31:747-752.
25. Boger R.H., Sullivan L.M., Schwedhelm E., et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009, 119:1592-1600.
26. Worthley M.I., Holmes A.S., Willoughby S.R., et al. The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration. J Am Coll Cardiol 2007, 49:304-310.
27. Yasuda S., Miyazaki S., Kanda M., et al. Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. Eur Heart J 2006, 27:1159-1165.
28. Heutling D., Schulz H., Nickel I., et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008, 93:82-90.
29. Krzyzanowska K., Mittermayer F., Shnawa N., et al. Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with type 2 diabetes and albuminuria. Diabet Med 2007, 24:81-86.
30. Schnabel R., Blankenberg S. Oxidative stress in cardiovascular disease: successful translation from bench to bedside?. Circulation 2007, 116:1338-1340.
31. Schulze F., Wesemann R., Schwedhelm E., et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004, 42:1377-1383.